ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of Oral ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Beijing InnoCare Pharma Tech Co., Ltd.
552 participants
Nov 14, 2024
INTERVENTIONAL
Conditions
Summary
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ICP-332 will be administered as tablet
ICP-332 Placebo will be administered as tablet
Locations(62)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06775860